XML 15 R5.htm IDEA: XBRL DOCUMENT v3.25.2
Consolidated Statements of Change in Stockholders' Equity (Unaudited) - USD ($)
Preferred Stock [Member]
Series A Convertible Preferred Stock [Member]
Preferred Stock [Member]
Series B Convertible Preferred Stock [Member]
Preferred Stock [Member]
Series C Convertible Preferred Stock [Member]
Preferred Stock [Member]
Series C-1 Convertible Preferred Stock [Member]
Preferred Stock [Member]
Series D Convertible Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
AOCI Attributable to Parent [Member]
Retained Earnings [Member]
Total
Balances at Mar. 31, 2024 $ 141 $ 16,441 $ (1,805,748) $ (1,789,166)
Balances, shares at Mar. 31, 2024 5,000,000        
Change in foreign currency (4,190) (4,190)
Forgiveness of related party payables 319,761 319,761
Cash received for founders’ shares 200 200
Shares issued in connection with exchange agreement 44,560 44,560
Shares issued in connection with exchange agreement, shares   17,000       800,000        
Net loss for the period (324,355) (324,355)
Balance at Jun. 30, 2024 364,662 12,251 (2,130,103) (1,753,190)
Balance, shares at Jun. 30, 2024 17,000 5,800,000        
Balances at Mar. 31, 2025 455,657 (11,010) (5,397,606) (4,952,959)
Balances, shares at Mar. 31, 2025 17,000 5,800,000        
Change in foreign currency (117,219) (117,219)
Net loss for the period (5,057,523) (5,057,523)
Issuance of Series A Convertible Preferred Stock to officers
Issuance of Series A Convertible Preferred Stock to officers, shares 2,000                  
Adjustment of shares in reverse merger $ 54 (54)
Adjustment of shares in reverse merger, shares (2,000) (17,000)       (5,262,451)        
Shares issued in connection with Phytanix Bio purchase $ 1 $ 12 1,813,361 (130,015) 1,683,359
Shares issued in connection with Phytanix Bio purchase, shares     5,705 950,000 20,000 117,690        
Shares issued for cash $ 5 395,469 $ 395,474
Shares issued for cash, shares           51,203       51,203
Shares issued for warrant exercises $ 115 3,949,615 $ 3,949,730
Shares issued for warrant exercises, shares           1,145,928        
Stock-based compensation 125,127 125,127
Rounding from reverse split
Rounding from reverse split, shares           (3,920)        
Balance at Jun. 30, 2025 $ 1 $ 186 $ 6,739,175 $ (258,244) $ (10,455,129) $ (3,974,011)
Balance, shares at Jun. 30, 2025 5,705 950,000 20,000 1,848,450